Log In
BCIQ
Print this Print this
 

E6011

  Manage Alerts
Collapse Summary General Information
Company Eisai Co. Ltd.
DescriptionAnti-fractalkine monoclonal antibody
Molecular Target
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$37.7M

$37.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/15/2015

$37.7M

$37.7M

0

Get a free BioCentury trial today